Volitionrx (VNRX) Income from Continuing Operations (2012 - 2025)
Volitionrx (VNRX) posted Income from Continuing Operations of 260595.0 for Q4 2025, up 929.05% on a QoQ basis from 31433.0 in Q3 2025, and down 49.54% year-over-year from 516444.0 in Q4 2024.
Volitionrx (VNRX) Income from Continuing Operations (2012 - 2025) Analysis & Trends
Volitionrx's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 260595.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 49.54% year-over-year to 260595.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5677082.0 (up 31.64% YoY) and the FY2025 annual result came in at 146302.0, down 49.58% from the prior year.
- Income from Continuing Operations was 260595.0 for Q4 2025 at Volitionrx, up from 31433.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 516444.0 in Q4 2024 and bottomed at 10103412.0 in Q2 2023.
- A 5-year average of 2560071.05 and a median of 37528.5 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 791.1% — and 2023, when it sank 13369.88%.
- Volitionrx's Income from Continuing Operations stood at 73088.0 in 2021, then grew by 28.74% to 94092.0 in 2022, then slumped by 9442.17% to 8790236.0 in 2023, then jumped by 105.88% to 516444.0 in 2024, then tumbled by 49.54% to 260595.0 in 2025.
- Business Quant data shows VNRX's Income from Continuing Operations at 260595.0 in Q4 2025, 31433.0 in Q3 2025, and 29992.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Volitionrx | 109,643.10 | -2.35 Mn | - | 260,595.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 260,595.00 |
| Sep 30, 2025 | -31,433.00 |
| Jun 30, 2025 | 29,992.00 |
| Mar 31, 2025 | -5.94 Mn |
| Dec 31, 2024 | 516,444.00 |
| Sep 30, 2024 | -47,049.00 |
| Jun 30, 2024 | 74,629.00 |
| Mar 31, 2024 | -8.85 Mn |
| Dec 31, 2023 | -8.79 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Jun 30, 2023 | -10.10 Mn |
| Mar 31, 2023 | -9.63 Mn |
| Dec 31, 2022 | 94,092.00 |
| Sep 30, 2022 | 69,305.00 |
| Jun 30, 2022 | 82,302.00 |
| Mar 31, 2022 | 83,977.00 |
| Dec 31, 2021 | 73,088.00 |
| Sep 30, 2021 | 45,065.00 |
| Jun 30, 2021 | 47,539.00 |
| Mar 31, 2021 | 9,424.00 |